Formulary
Atovaquone with proguanil hydrochloride: Indications, Dosing, Side Effects and Interactions
Atovaquone with proguanil hydrochloride clinical drug profile including indications, dosing, side effects, cautions and interactions.
MedNext Academy | 4 min read
Atovaquone with proguanil hydrochloride: Indications, Dosing, Side Effects and Interactions
Atovaquone with proguanil hydrochloride clinical drug profile including indications, dosing, side effects, cautions and interactions.
Indications and dose
**Prophylaxis of falciparum malaria, particularly where resistance to other antimalarial drugs suspected [using 250 mg/100 mg tablets]**
- **Adult** (By Mouth): (body-weight 40 kg and above) 1 tablet once daily, to be started 1-2 days before entering endemic area and continued for 1 week after leaving.
**Prophylaxis of falciparum malaria, particularly where resistance to other antimalarial drugs suspected [using 62.5 mg/25 mg tablets]**
- **Adult** (By Mouth): (body-weight 30-39 kg) 3 tablets once daily, to be started 1-2 days before entering endemic area and continued for 1 week after leaving.
**Treatment of acute uncomplicated falciparum malaria [using 250 mg/100 mg tablets],Treatment of non-falciparum malaria [using 250 mg/100 mg tablets]**
- **Adult** (By Mouth): Treatment of acute uncomplicated falciparum malaria [using 250 mg/100 mg tablets], Treatment of non-falciparum malaria [using 250 mg/100 mg tablets] 4 tablets once daily for 3 days.
**Prophylaxis of falciparum malaria, particularly where resistance to other antimalarial drugs suspected [using 250 mg/100 mg tablets] for atovaquone with proguanil hydrochloride**
- **Child (body-weight 40 kg and above)** (By mouth): 1 tablet once daily, to be started 1-2 days before entering endemic area and continued for 1 week after leaving.
**Prophylaxis of falciparum malaria, particularly where resistance to other antimalarial drugs suspected [using 62.5 mg/25 mg tablets] for atovaquone with proguanil hydrochloride**
- **Child (body-weight 5-7 kg)** (By mouth): 0.5 tablet once daily, to be started 1-2 days before entering endemic area and continued for 1 week after leaving.
- **Child (body-weight 8-9 kg)** (By mouth): 0.75 tablet once daily, to be started 1-2 days before entering endemic area and continued for 1 week after leaving.
- **Child (body-weight 10-19 kg)** (By mouth): 1 tablet once daily, to be started 1-2 days before entering endemic area and continued for 1 week after leaving.
- **Child (body-weight 20-29 kg)** (By mouth): 2 tablets once daily, to be started 1-2 days before entering endemic area and continued for 1 week after leaving.
- **Child (body-weight 30-39 kg)** (By mouth): 3 tablets once daily, to be started 1-2 days before entering endemic area and continued for 1 week after leaving.
- **Child (body-weight 40 kg and above)** (By mouth): Use 250 mg/100 mg tablets.
**Treatment of acute uncomplicated falciparum malaria [using 250 mg/100 mg tablets], Treatment of non-falciparum malaria [using 250 mg/100 mg tablets] for atovaquone with proguanil hydrochloride**
- **Child (body-weight 11-20 kg)** (By mouth): 1 tablet once daily for 3 days.
- **Child (body-weight 21-30 kg)** (By mouth): 2 tablets once daily for 3 days.
- **Child (body-weight 31-40 kg)** (By mouth): 3 tablets once daily for 3 days.
- **Child (body-weight 41 kg and above)** (By mouth): 4 tablets once daily for 3 days.
**Treatment of acute uncomplicated falciparum malaria [using 62.5 mg/25 mg tablets], Treatment of non-falciparum malaria [using 62.5 mg/25 mg tablets] for atovaquone with proguanil hydrochloride**
- **Child (body-weight 5-8 kg)** (By mouth): 2 tablets once daily for 3 days.
- **Child (body-weight 9-10 kg)** (By mouth): 3 tablets once daily for 3 days.
- **Child (body-weight 11 kg and above)** (By mouth): Use 250 mg/100 mg tablets.
Cautions
For atovaquone with proguanil hydrochloride Diarrhoea or vomiting (reduced absorption of atovaquone); efficacy not evaluated in cerebral or complicated malaria (including hyperparasitaemia, pulmonary oedema or renal failure)
Side effects
For atovaquone with proguanil hydrochloride Common or very common Abdominal pain; appetite decreased; cough; depression; diarrhoea; dizziness; fever; headache; nausea; skin reactions; sleep disorders; vomiting Uncommon Alopecia; anxiety; blood disorder; hyponatraemia; oral disorders; palpitations Frequency not known Hallucination; hepatic disorders; photosensitivity reaction; seizure; Stevens-Johnson syndrome; tachycardia; vasculitis
Pregnancy
For atovaquone with proguanil hydrochloride When used for Prophylaxis of malaria: UKHSA advises avoid but may be considered during second and third trimesters if no suitable alternative available. See also Pregnancy in Malaria, prophylaxis . When used for Treatment of malaria: Use only if potential benefit outweighs risk. M
Breast feeding
For atovaquone with proguanil hydrochloride Specialist sources indicate use only if no suitable alternative available.
Renal impairment
For atovaquone with proguanil hydrochloride Avoid for malaria prophylaxis (and if possible for malaria treatment) if creatinine clearance less than 30 mL/minute, M see Prescribing in renal impairment .
Medicinal forms
Clinical governance
**Author:** MedNext Clinical Team. **Clinical reviewer:** Dr Shameer Deen, MBBS, MS, MRCS. **Sources:** BNF, Indian Pharmacopoeia, CIMS India. **Correction:** Report errors at support@mednext.academy.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- Growing visual cheat sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Subject HubPharmacology Hub
All pharmacology resources in one place.
Drug SchedulesIndian Drug Schedules
Schedule H, H1, X and G classifications.
FormularyBrowse all drugs
Search 1,850+ drug profiles.
Study Atovaquone with proguanil hydrochloride in the MedNext app
Challenge yourself with targeted pharmacology MCQs on this drug class. Every explanation links back to the chapter that teaches the concept.
Start drug challengeExplore the full formulary

